Ovagen Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Ovagen?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Liver protection, gastrointestinal mucosal defense, epigenetic gene regulation, hepatocyte regeneration, aging biology
• First Developed: Late 20th century, Saint Petersburg Institute of Bioregulation and Gerontology
• Molecular Weight: 375.37 g/mol
• Research Status: Preclinical; no published human clinical trials identified in Western literature
• Key Mechanisms: Nuclear translocation via PEPT1/PEPT2 transporters, chromatin remodeling, DNA methylation modulation, antioxidant enzyme upregulation
• Published Studies: Primary data from Russian-language gerontological research; most Western citations relate to the structural analog Livagen (KEDA tetrapeptide)
• Clinical Trial Status: No Phase I, II, or III human trials identified; human clinical data absent
• Regulatory Classification: Research use only; not approved for human therapeutic application in any major jurisdiction

What is Ovagen?

Ovagen is a synthetic tripeptide consisting of three amino acids: glutamic acid, aspartic acid, and leucine, abbreviated as Glu-Asp-Leu or EDL. It belongs to a class of compounds called cytogene peptide bioregulators, ultrashort synthetic peptides designed to replicate the active sites of naturally occurring tissue-specific regulatory proteins. Researchers developed it specifically to target liver and gastrointestinal tissue through a proposed epigenetic mechanism rather than the receptor-binding pathways that characterize most bioactive peptides.

The compound was developed by Professor Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as part of a decades-long research program investigating how short peptides derived from animal organ extracts regulate gene expression in a tissue-specific manner. The research philosophy behind Ovagen holds that aging disrupts normal gene expression patterns in organ-specific cells, and that introducing small regulatory peptides can partially restore more youthful transcriptional programs through epigenetic mechanisms.

Researchers study Ovagen for its proposed ability to enter cell nuclei and interact directly with DNA and histone proteins. This mechanism distinguishes it from classical peptide drugs that bind surface receptors. The two acidic residues in the EDL sequence (glutamic acid and aspartic acid) combined with the hydrophobic leucine create a dual chemical character that is hypothesized to enable membrane penetration while maintaining aqueous solubility.

Important disambiguation: Three entirely separate entities share similar names. The Ovagen EDL tripeptide described in this article is distinct from a commercial product containing ovine follicle-stimulating hormone used in reproductive medicine, and from an Irish biotechnology company called Ovagen that develops germ-free embryonated chicken eggs for vaccine manufacturing. These entities share no research overlap, mechanisms, or applications. Researchers searching for Ovagen literature should verify they are retrieving results specific to the Glu-Asp-Leu tripeptide sequence.

The evidence base for Ovagen consists primarily of Russian-language gerontological research, with much of the supporting Western-literature data coming from studies on Livagen, a closely related tetrapeptide (Lys-Glu-Asp-Ala / KEDA) that shares overlapping sequence elements with the EDL tripeptide. No recent peer-reviewed publications (2021 to present) specifically examining Ovagen EDL were identified in Western scientific literature during the preparation of this article, which itself reflects a meaningful gap in the global research record.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

The EDL sequence places two acidic residues (glutamic acid and aspartic acid) immediately adjacent to a hydrophobic leucine. This architecture creates a molecule with dual chemical character. The acidic residues confer water solubility and hydrophilicity, while the leucine portion facilitates interaction with hydrophobic environments including cell membranes and nuclear structures. Researchers propose this dual character enables the peptide to remain soluble in aqueous biological environments while still penetrating membrane barriers to access the nucleus.

Ovagen’s molecular weight of 375.37 g/mol places it among the smallest characterized bioregulatory peptides. This minimal size is considered functionally significant in the cytogene model: the peptide represents what researchers describe as the minimum functional unit derived from larger tissue-specific regulatory sequences. The small size facilitates membrane penetration and nuclear access.

The peptide binds preferentially to AT-rich DNA stretches where regulatory interactions are proposed to occur. Its structural relationship to Livagen (Lys-Glu-Asp-Ala) is direct: the EDL tripeptide sequence is contained within the KEDA tetrapeptide. This overlap makes Livagen research the closest available analogue data for understanding Ovagen’s proposed mechanisms, though the compounds are not identical and effects may differ.

A related variant, EDP (Glu-Asp-Phe), substitutes phenylalanine for leucine in the terminal position. In HIV-1 protease inhibition studies, EDP shows roughly 2.5-fold greater potency than EDL (Ki approximately 20 micromolar versus 50 micromolar), suggesting the terminal hydrophobic residue influences binding affinity in specific contexts.

Mechanisms of Action Being Investigated

Ovagen’s proposed mechanisms center on direct nuclear interaction rather than surface receptor binding. Researchers studying this compound and its structural analogs have described several distinct pathways that together constitute the cytogene bioregulator model.

Nuclear Translocation via PEPT1 and PEPT2 Transporters

Ovagen crosses cell membranes using proton-coupled oligopeptide transporters, specifically PEPT1 and PEPT2, members of the POT (Proton-coupled Oligopeptide Transporter) family [1]. These transport proteins normally shuttle di- and tripeptides from digested food across intestinal and renal epithelia. Ovagen exploits this existing transport system for cellular entry.

After crossing the plasma membrane, the peptide penetrates nuclear membranes to access DNA directly. Liver and gastrointestinal tissues express particularly high levels of PEPT1 and PEPT2 transporters, which researchers propose explains the tissue-specific distribution of Ovagen’s effects. This transporter-dependent nuclear access is the mechanistic foundation for all downstream epigenetic activity described in the cytogene model [1].

Chromatin Remodeling and Gene Expression Normalization

Once inside the nucleus, Ovagen and its structural analogs bind nucleosomal DNA and histone proteins. This binding modulates DNA methylation patterns, controlling whether specific genes are activated or silenced. A key proposed effect is de-heterochromatinization: reduction of age-related DNA condensation in hepatocytes and gastrointestinal mucosal cells [1,2].

In aging cells, regions of the genome become excessively condensed (heterochromatin), making previously active genes inaccessible for transcription. The cytogene model proposes that short acidic peptides reverse this condensation by altering the electrostatic interactions between DNA and histone proteins, making silenced gene regions available for transcription again. Studies on the closely related Livagen tetrapeptide demonstrated activation of ribosomal genes and decondensation of pericentromeric heterochromatin in lymphocytes from elderly individuals, providing the primary experimental support for this proposed mechanism [2].

Gene Expression Targets: Upregulation and Downregulation

Research on Ovagen and its structural analogs identifies opposing effects on different gene classes. Upregulated pathways include detoxification enzyme systems, protein synthesis machinery, cellular repair genes, and antioxidant defense components, particularly catalase and glutathione peroxidase [3,4]. The antioxidant upregulation effect appears especially pronounced for glutathione peroxidase in available data.

Downregulated pathways include pro-fibrotic signaling and age-related senescence markers. Studies using the Livagen analog showed a 6-fold decrease in p53 expression and an 18-fold increase in Ki-67 expression (a proliferation marker) in aged liver tissue, suggesting the peptide shifts aged hepatocytes from a senescent toward a proliferative state [5]. The p16 and p21 cyclin-dependent kinase inhibitors, which enforce cell cycle arrest in senescent cells, are also reported as downregulation targets in related cytogene research.

Anti-Fibrotic Signaling

Ovagen research proposes regulation of collagen deposition and extracellular matrix turnover as mechanisms relevant to liver fibrosis prevention. The proposed pathway involves inhibition of hepatic stellate cell activation, the primary cellular driver of liver fibrosis. However, direct Ovagen-specific data on anti-fibrotic mechanisms is limited; most available evidence is inferred from related peptide research on the Livagen tetrapeptide and broader liver bioregulator studies [3,6].

Antioxidant Defense Modulation

Cell model studies show reduction in lipid peroxidation and oxidatively modified proteins following exposure to Ovagen and related cytogene peptides. The mechanism involves upregulation of enzymatic antioxidant systems rather than direct radical scavenging. Catalase activity increases, improving hydrogen peroxide clearance, while glutathione peroxidase upregulation enhances protection against lipid hydroperoxides [4]. These findings position Ovagen research within the broader field of oxidative stress modulation in hepatocyte biology.

HIV-1 Protease Inhibition

The EDL sequence competitively inhibits HIV-1 protease with a Ki value of approximately 50 micromolar [7]. The peptide sequence was derived from the viral transframe region of the Gag-Pol polyprotein, where similar short sequences appear naturally. A crystallographic structure of the EDL-HIV-1 protease complex has been resolved, confirming direct binding at the protease active site. Ovagen is described in this context as among the smallest and most water-soluble protease inhibitors characterized structurally.

The inhibition constant of 50 micromolar represents very weak potency relative to clinical antiviral drugs, which typically achieve effective inhibition in the nanomolar range. This finding is mechanistically interesting as a demonstration of peptide-protease interaction but does not translate to antiviral efficacy in biological systems. The related EDP variant (Glu-Asp-Phe) shows approximately 2.5-fold greater potency at 20 micromolar Ki, but remains similarly distant from clinically useful potency thresholds [7].

Hepatocyte Protein Synthesis and Circadian Rhythm Restoration

Studies on the Livagen analog in aged rat hepatocyte cultures showed substantial enhancement of protein synthesis rates in older cells, with treated aged cells approaching protein synthesis levels characteristic of young cells [5]. A parallel finding involves restoration of intracellular circadian rhythms of biosynthesis. Aging disrupts the normal oscillatory patterns of cellular protein production, and cytogene peptide treatment in these models partially restored rhythmic synthesis patterns. These findings represent the most quantitatively striking results in the available literature but derive from the Livagen analog rather than Ovagen directly.

Major Areas of Research

Ovagen and its structural analogs are investigated across several biological systems, with liver and gastrointestinal applications representing the primary research focus. The following areas receive coverage in the available literature.

Hepatoprotection and Liver Function Research

Liver protection is Ovagen’s primary proposed research application and the area with the most supporting data, though much of it derives from the structurally related Livagen tetrapeptide. Experimental liver pathology models using chemical hepatotoxins show hepatoprotective effects, with normalization of liver function parameters and prevention of fibrotic changes at the cellular level [3,6].

Age-dependent effects are a consistent finding across hepatoprotection studies: the protective and regenerative effects of cytogene peptides appear most pronounced in older animals, with younger animals showing smaller or sometimes opposing responses. This age-specificity is central to the gerontological framing of Ovagen research, positioning the compound as particularly relevant to age-related hepatic decline rather than acute liver injury across all age groups [3].

Specific hepatotoxicity models used in preclinical research include carbon tetrachloride-induced damage, acetaminophen toxicity, alcohol-related liver injury, and drug-induced hepatotoxicity. Cirrhosis prevention and hepatic fibrosis mechanisms have also been studied in experimental systems.

Key Research Highlights:

• Normalization of liver function parameters in experimental pathology models
• Prevention of fibrotic changes at the cellular level in aged tissue models
• Restoration of immune and antioxidant status during experimental hepatitis
• Maximal hepatoprotective effects observed in older animals rather than younger ones

Gastrointestinal Tract Protection Studies

Gastrointestinal research examines Ovagen’s proposed protective effects on mucosal barriers and digestive function. Animal model studies indicate protective activity against gastrointestinal damage from antibiotic therapy, with reduced mucosal disruption compared to controls [3]. Potential protective effects during chemotherapy administration have been investigated in preclinical settings.

A notable finding from the Livagen analog in rat studies involves age-divergent effects on digestive enzyme activity. Oral administration for two weeks produced opposite effects depending on animal age: reduction in digestive enzyme activity in young animals but an increase approaching youthful levels in old animals [8]. This bidirectional, age-specific response pattern aligns with the broader cytogene model, which proposes that these peptides normalize rather than uniformly upregulate or suppress biological activity.

Key Research Highlights:

• Protection against antibiotic-induced gastrointestinal mucosal damage in animal models
• Age-divergent digestive enzyme modulation (decrease in young, normalization in old animals)
• Preclinical investigation of mucosal barrier integrity during chemotherapy exposure

Epigenetic and Aging Biology Research

Aging research represents the theoretical foundation of the entire cytogene bioregulator program, and Ovagen sits within this broader framework. The primary experimental model demonstrating epigenetic mechanisms involves lymphocyte chromatin from elderly human donors treated with Livagen. These studies showed activation of ribosomal genes and decondensation of pericentromeric heterochromatin, regions that become increasingly condensed with age and contribute to reduced transcriptional capacity in older cells [2].

Gene expression studies in human mesenchymal stem cell aging cultures have examined modulation by short peptides of the cytogene class, providing a cell biology framework for understanding how these compounds might influence the transcriptional landscape of aging cells [9]. The conceptual model holds that ultrashort peptides derived from tissue-specific proteins can partially reverse age-related epigenetic drift, restoring more youthful patterns of gene activity without permanently altering the genetic sequence.

Key Research Highlights:

• Decondensation of pericentromeric heterochromatin in lymphocytes from elderly donors
• Activation of ribosomal genes in aged cell models treated with structural analogs
• Modulation of aging-related gene expression programs in stem cell cultures
• Restoration of youthful chromatin architecture in senescent hepatocytes

HIV-1 Protease Inhibition and Antiviral Biochemistry

Ovagen’s EDL sequence inhibits HIV-1 protease competitively at a Ki of approximately 50 micromolar, a finding with mechanistic interest for understanding peptide-protease interactions but limited therapeutic relevance due to the weak inhibition constant [7]. The crystallographic resolution of the EDL-HIV-1 protease complex makes Ovagen one of the structurally characterized minimal peptide inhibitors of this enzyme.

The sequence origin in the viral transframe region of Gag-Pol raises questions about whether endogenous viral peptides may modulate protease activity during viral replication, an area of basic virology interest separate from therapeutic development. Research on related EDP (Glu-Asp-Phe) variants with improved potency suggests the terminal hydrophobic residue is a modifiable position for structure-activity relationship studies.

Key Research Highlights:

• Competitive HIV-1 protease inhibition with resolved crystal structure of peptide-enzyme complex
• Ki of 50 micromolar for EDL; Ki of 20 micromolar for related EDP variant
• Origin of sequence in viral transframe region with implications for viral biology research
• Water solubility advantage over larger characterized protease inhibitors

Antioxidant Defense and Oxidative Stress Modulation

Oxidative stress research on Ovagen and related cytogene peptides shows consistent reductions in lipid peroxidation markers and oxidatively modified proteins in cell models [4]. The mechanism operates through enzymatic upregulation rather than direct antioxidant activity, with catalase and glutathione peroxidase showing the most consistent increases. This distinguishes the proposed mechanism from simple radical scavenging compounds and aligns it with the broader epigenetic gene expression model, where changes in antioxidant enzyme gene activity mediate the observed effects.

Key Research Highlights:

• Reduced lipid peroxidation in cell model studies
• Upregulation of catalase and glutathione peroxidase enzymatic activity
• Reduced levels of oxidatively modified proteins in treated cell models

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Ovagen is noted in research materials for resistance to gastric degradation, a property that distinguishes it from many peptides that break down rapidly in the acidic stomach environment. This stability is attributed to its short sequence and structural features that resist peptidase cleavage. The peptide enters cells through PEPT1 and PEPT2 proton-coupled oligopeptide transporters, which are expressed throughout the intestinal epithelium and in renal tubular cells [1].

The cytogene model proposes oral bioavailability as a functional delivery route, with gastrointestinal absorptive cells serving as both entry points and target tissues. Liver distribution following intestinal absorption would occur through portal circulation, consistent with the hepatic targeting that characterizes proposed applications.

Distribution and Metabolism

Tissue distribution reflects the expression pattern of PEPT1 and PEPT2 transporters. Liver and gastrointestinal tissues, which express these transporters at high levels, are proposed primary distribution targets. This transporter-dependent targeting provides the mechanistic basis for the organ selectivity observed in preclinical studies.

Plasma half-life has not been fully characterized in published studies. Standard pharmacokinetic behavior for tripeptides predicts rapid clearance from systemic circulation, typically minutes to tens of minutes. Nuclear retention and the duration of epigenetic modifications following peptide clearance represent an important unresolved question: the biological effects described in research may outlast plasma presence considerably, but the temporal dynamics of chromatin changes have not been formally characterized.

Delivery Methods Under Investigation

• Oral administration: Supported by gastric stability properties and PEPT1 expression in intestinal epithelium; used in available animal studies
• Subcutaneous injection: Standard route for many research peptide studies; direct systemic distribution
• Intraperitoneal injection: Used in rodent experimental models for consistent systemic delivery

Excretion and Clearance

Tripeptides of this size are subject to standard peptide degradation pathways including serum peptidases and renal filtration. Specific clearance and excretion data for Ovagen have not been published in accessible literature. Given the proposed nuclear mechanism of action, the relationship between systemic clearance and duration of biological effect remains an important uncharacterized parameter.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data No published Phase I, II, or III human clinical trials for Ovagen (Glu-Asp-Leu) were identified in any language during preparation of this article. Human pharmacokinetics, safety, tolerability, and efficacy data are completely absent from the accessible scientific record. The compound cannot be considered to have an established human safety profile.

Western Literature Availability Recent peer-reviewed publications specifically examining Ovagen EDL as a research peptide are absent from Western scientific literature (2021 to present). Primary research on this compound exists predominantly in Russian-language publications from the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated groups. This geographic concentration limits independent replication and peer review by the broader international scientific community.

Mechanistic Understanding Primary DNA binding sites have not been definitively identified. Specific gene targets and transcriptional programs affected by Ovagen remain unclear. Tissue-specific targeting mechanisms are incompletely understood. The contributions of active metabolites versus the parent peptide to observed biological effects are unknown. Temporal dynamics of epigenetic changes and the duration of effects following peptide clearance have not been established. The relationship between chromatin modifications observed in cell models and functional biological outcomes in intact organisms requires further investigation.

Livagen Analog Reliance A substantial portion of the mechanistic data cited in Ovagen research derives from studies on Livagen (Lys-Glu-Asp-Ala), a structurally related but non-identical tetrapeptide. While the shared EDL sequence provides reasonable grounds for inferring mechanistic overlap, direct Ovagen-specific experimental confirmation of these effects is limited.

Methodological Considerations Most available data comes from animal models and cell cultures. Study protocols vary considerably across the Russian-language literature, limiting systematic comparison. Independent replication by groups outside the originating institute is largely absent from the record. Long-term safety and efficacy data beyond short experimental treatment periods do not exist.

Areas Needing Further Investigation

• Formal human pharmacokinetic studies establishing absorption, distribution, metabolism, and excretion parameters
• Independent replication of chromatin remodeling findings by research groups outside the originating institute
• Direct comparison studies between Ovagen (EDL) and Livagen (KEDA) to establish which effects are compound-specific versus class-wide
• Characterization of the temporal relationship between peptide clearance and persistence of epigenetic modifications
• Long-term safety assessment in animal models as a prerequisite for human research consideration

Regulatory and Research Status

Current Classification

FDA Status Ovagen is not approved by the FDA for any human therapeutic application. It has not undergone the investigational new drug (IND) application process required to initiate human clinical trials in the United States. The compound is available for legitimate laboratory research purposes only.

WADA Status Ovagen does not appear on the WADA prohibited list as a specifically named compound. However, WADA’s prohibited list includes categories for peptide hormones, growth factors, related substances, and mimetics that may encompass bioregulatory peptides depending on their biological activity. Athletes subject to anti-doping testing should not assume unlisted compounds are permitted, and should seek formal guidance before any exposure.

International Perspective The compound occupies research-chemical status in major international markets. No regulatory authority in the EU, UK, Canada, Australia, or Japan has reviewed or approved Ovagen for human use. Its primary development history in Russia means it exists outside the major Western drug approval frameworks entirely. Russian gerontological research traditions recognize peptide bioregulators as a distinct compound class, but this recognition does not constitute pharmaceutical approval for therapeutic use.

Research Community Approach

Active research on cytogene peptide bioregulators continues primarily within the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated Russian research institutions. The broader international research community has engaged with this compound class to a limited degree. Legitimate research requires institutional biosafety oversight, appropriate animal care protocols for in vivo work, and compliance with applicable regulations in the researcher’s jurisdiction.

Future Research Directions

The most critical gap is human pharmacokinetic and safety data. No responsible pathway toward human application exists without first establishing basic safety parameters in properly conducted human studies. Independent replication of the chromatin remodeling and hepatoprotective findings by international research groups would substantially strengthen the evidence base. Mechanistic studies using modern genomics tools (chromatin immunoprecipitation sequencing, RNA sequencing of treated versus untreated aged cells) could clarify the gene expression targets that remain undefined despite decades of cytogene peptide research.

Key Research Findings

Chromatin Remodeling in Aged Lymphocytes (Livagen Analog Study)

Research Focus: Effects of the related KEDA tetrapeptide on chromatin structure in lymphocytes from elderly human donors Key Results: Activation of ribosomal genes; decondensation of pericentromeric heterochromatin in aged lymphocyte cultures; restoration of transcriptional capacity in previously repressed gene loci Significance: Provides the primary experimental evidence for the chromatin remodeling mechanism proposed for the entire cytogene peptide class, including Ovagen Limitations: Performed with Livagen (KEDA), not Ovagen (EDL) directly; lymphocyte findings may not generalize to liver tissue; independent replication not established [2]

Hepatocyte Regeneration and Proliferation (Livagen in Rat Cultures)

Research Focus: Effects of Livagen tetrapeptide on aged rat hepatocyte cultures Key Results: 18-fold increase in Ki-67 expression (proliferation marker) in aged liver tissue; 6-fold decrease in p53 expression (apoptosis/senescence marker); enhanced protein synthesis rates approaching levels of young cells; restoration of disrupted intracellular circadian rhythms of biosynthesis Significance: Most quantitatively dramatic findings in the cytogene liver research literature; directly relevant to the hepatoprotective applications proposed for Ovagen Limitations: Livagen data, not Ovagen-specific; cell culture model; rat hepatocytes; no human confirmation [5]

Digestive Enzyme Modulation with Age-Dependent Divergence

Research Focus: Effect of oral Livagen administration on digestive enzyme activity across age groups in rats Key Results: Two-week oral administration reduced digestive enzyme activity in young animals while increasing it toward youthful levels in old animals; modulation occurred in both gastrointestinal and non-digestive organs Significance: Establishes the age-normalization pattern as a consistent feature of cytogene peptide biology, distinct from simple stimulation or suppression Limitations: Livagen analog; rat model only; mechanism of age-divergent response unexplained [8]

HIV-1 Protease Inhibition with Crystallographic Confirmation

Research Focus: Competitive inhibition of HIV-1 protease by the EDL tripeptide sequence Key Results: Ki approximately 50 micromolar for EDL; Ki approximately 20 micromolar for the related EDP variant; crystallographic structure of EDL-protease complex resolved; origin of sequence from viral transframe region confirmed Significance: Establishes Ovagen as a structurally characterized minimal peptide inhibitor of HIV-1 protease; provides mechanistic insight into peptide-protease interactions and potential natural regulation of viral replication Limitations: Micromolar potency is clinically insufficient for antiviral application; biological context of protease regulation by endogenous TFR-derived peptides remains speculative [7]

Antioxidant Enzyme Upregulation

Research Focus: Antioxidant defense modulation by cytogene peptides in cell models Key Results: Reduced lipid peroxidation; reduced oxidatively modified proteins; increased catalase and glutathione peroxidase activity; effect attributed to gene expression changes rather than direct scavenging Significance: Connects the epigenetic mechanism model to functional antioxidant outcomes measurable in standard cell biology assays Limitations: Cell model data; specific gene expression changes driving enzyme upregulation not fully mapped; species-specific enzyme responses may differ [4]

Nuclear Transport Mechanism Characterization

Research Focus: Cellular entry and nuclear translocation pathway for cytogene class peptides Key Results: PEPT1 and PEPT2 transporter-mediated uptake confirmed as primary entry mechanism; nuclear membrane penetration demonstrated; tissue specificity of effects linked to differential transporter expression Significance: Provides mechanistic foundation explaining how small peptides reach the nucleus and why effects concentrate in specific tissues with high transporter expression Limitations: Mechanistic characterization from 2022 remains to be confirmed independently; primary DNA binding sites within the nucleus not identified [1]

Frequently Asked Questions

What is Ovagen and what is it made of?

Ovagen is a synthetic tripeptide composed of three amino acids: glutamic acid, aspartic acid, and leucine, often abbreviated as Glu-Asp-Leu or EDL. It was developed by researchers in Russia as part of a class of compounds called cytogene peptide bioregulators. Ovagen peptide research focuses on its proposed ability to enter cell nuclei and interact directly with DNA to modulate gene expression, particularly in liver and gastrointestinal tissue.

What makes Ovagen different from most research peptides?

Most research peptides work by binding to receptors on the cell surface, triggering signaling cascades inside the cell. Ovagen research proposes a different mechanism: the peptide enters the nucleus directly and interacts with DNA and histone proteins to modify how genes are expressed. This places it in the epigenetic research category rather than classical receptor pharmacology, though the specific nuclear targets remain incompletely characterized.

How long has Ovagen been studied?

Ovagen was developed at the Saint Petersburg Institute of Bioregulation and Gerontology in the late 20th century as part of a research program spanning more than four decades. The broader cytogene peptide bioregulator program, in which Ovagen sits, has an extensive research history within Russian gerontological science. However, independent international research on Ovagen specifically is limited, and no peer-reviewed publications specifically examining Ovagen EDL were identified in Western scientific literature from 2021 onward.

Is Ovagen the same as the ovulation drug also called Ovagen?

No. The Ovagen tripeptide (Glu-Asp-Leu) described in this research article has no connection to a separately marketed commercial product containing ovine follicle-stimulating hormone that shares a similar name and is used in reproductive medicine. They are entirely different substances with different origins, structures, mechanisms, and proposed applications. A third unrelated entity called Ovagen is an Irish biotechnology company that develops vaccine production systems. Researchers should verify they are referencing the correct compound when searching literature or sourcing research materials.

What does current research say about Ovagen’s safety?

Published safety data for Ovagen in humans does not exist. No human clinical trials for the Glu-Asp-Leu tripeptide have been identified in any language. Animal model studies have not reported notable adverse effects at research doses, and the compound’s small size and proposed endogenous-like mechanism suggest limited systemic toxicity, but this cannot be assumed without formal safety studies. Ovagen is classified for research use only and is not approved for human therapeutic application in any jurisdiction.

References

1. Khavinson, V.K., Linkova, N.S., Dyatlova, A.S., Kantemirova, R., & Morozov, A.V. (2022). Short peptides: cellular and molecular mechanisms of the geroprotective effect. International Journal of Molecular Sciences, 23(14), 7733. PubMed

2. Lezhava, T., Monaselidze, J., Jokhadze, T., Kakauridze, N., & Khavinson, V. (2003). Epigenetic mechanism of action of some peptide bioregulators: activation of ribosomal genes and decondensation of pericentromeric heterochromatin. Bulletin of Experimental Biology and Medicine, 135(3), 267-269. PubMed

3. Kuznik, B.I., Pateyuk, A.V., Rusaeva, N.S., Davydov, S.O., & Khavinson, V.K. (2020). Effects of tetrapeptide KEDA on functional state of the liver in hypophysectomized animals of different ages. Advances in Gerontology, 10(1), 77-86. PubMed

4. Khavinson, V.K., Tarnovskaya, S.I., Linkova, N.S., Chervyakova, N.A., Nichik, T.E., & Elashkina, E.V. (2014). Short peptides simulate cell renewal processes in vitro. Bulletin of Experimental Biology and Medicine, 156(6), 767-770. PubMed

5. Brodsky, V.Y., Nechaeva, N.V., Zvezdina, N.D., Malchenko, L.A., & Fateeva, V.I. (2001). Stimulation of protein synthesis rhythm in hepatocytes by the peptide Livagen in old rats. Izvestiya Akademii Nauk. Seriya Biologicheskaya, (4), 422-426. PubMed

6. Trofimova, S.V., Malinin, V.V., & Khavinson, V.K. (2021). Prospects for the use of peptide bioregulators in gastroenterology. EC Gastroenterology and Digestive System, 8(11), 43-47.

7. Louis, J.M., Dyda, F., Nashed, N.T., Kimmel, A.R., & Davies, D.R. (1998). Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry, 37(8), 2105-2110. PubMed

8. Timofeeva, N.M., Gromova, L.V., Egorova, V.V., Gruzdkov, A.A., & Khavinson, V.K. (2005). Effect of peptide bioregulators on the activity of enzymes in the small intestine and blood serum of young and old rats. Advances in Gerontology, 16, 92-96. PubMed

9. Ashapkin, V.V., Kutueva, L.I., Kurchashova, S.Y., & Kireev, I.I. (2020). Are there common mechanisms between the Hutchinson-Gilford progeria syndrome and natural aging? Frontiers in Genetics, 10, 1-14. PubMed

10. Khavinson, V.K., Popovich, I.G., Linkova, N.S., Mironova, E.S., & Ilina, A.R. (2021). Peptide regulation of gene expression: a systematic review. Molecules, 26(22), 7052. PubMed

11. Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules, 25(3), 609. PubMed

12. Linkova, N.S., Dyatlova, A.S., Medvedeva, E.V., Redichkina, A.A., & Khavinson, V.K. (2021). Geroprotective potential of short peptides. International Journal of Molecular Sciences, 22(24), 13540. PubMed

13. Khavinson, V.K., Linkova, N.S., Tarnovskaya, S.I., Chervyakova, N.A., Lavrova, N.V., & Nichik, T.E. (2016). Molecular mechanisms of biological activity of short peptides: activation of gene expression or direct interaction with cell receptors. Biology Bulletin, 43(3), 240-248.

14. Kvetnoy, I., Polyakova, V., Trofimov, A., Linkova, N., Kvetnaia, T., Yudintceva, N., Egorova, V., & Khavinson, V. (2022). Geroprotective mechanisms and therapeutic potential of epithalamine (pineal gland peptide extract). International Journal of Molecular Sciences, 23(8), 4163. PubMed

15. Khavinson, V.K., & Malinin, V.V. (2005). Gerontological aspects of genome peptide regulation. Karger.

16. Kuznik, B.I., Khavinson, V.K., Ryzhak, G.A., & Tarnovskaya, S.I. (2012). Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuroendocrinology Letters, 33(6), 677-681. PubMed